Advances in aerosols: Adult respiratory disease

Journal of Aerosol Medicine: Deposition, Clearance, and Effects in the Lung

Volumn 19, Issue 1, 2006, Pages 36-46

  Smaldone, Gerald C ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

Antibiotics; Control of breathing; Cyclosporine; Facemasks; Interferon

Indexed keywords

ANTIBIOTIC AGENT; CYCLOSPORIN; GAMMA INTERFERON; TUBERCULOSTATIC AGENT;

ADULT DISEASE; AEROSOL; AIRWAY; BREATHING PATTERN; CAREGIVER; CLINICAL TRIAL; DEVICE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG INTOXICATION; DRUG TARGETING; FACE MASK; FEEDBACK SYSTEM; GRAFT REJECTION; HUMAN; INTENSIVE CARE UNIT; INTUBATION; LUNG ALVEOLUS; LUNG FIBROSIS; LUNG TRANSPLANTATION; LUNG TUBERCULOSIS; MAN MACHINE INTERACTION; METERED DOSE INHALER; NEBULIZER; PATIENT SAFETY; RESPIRATION CONTROL; RESPIRATORY TRACT DISEASE; REVIEW; SUPERINFECTION; SYSTEMIC DISEASE; VENTILATOR ASSOCIATED PNEUMONIA;

ADMINISTRATION, INHALATION; ADULT; AEROSOLS; ANTI-BACTERIAL AGENTS; CYCLOSPORINE; HUMANS; INTERFERONS; NEBULIZERS AND VAPORIZERS; RESPIRATORY PHYSIOLOGY; RESPIRATORY TRACT DISEASES;

EID: 33645473085     PISSN: 08942684     EISSN: None     Source Type: Journal    
DOI: 10.1089/jam.2006.19.36     Document Type: Review

References (31)

1. Dolovich, M.B., R.C. Ahrens, D. Hess, et al. 2005. Device selection and outcomes of aerosol therapy: ACCP/ACAAI evidence based guidelines. Chest 127: 335-371.
2. Smaldone, G.C., P. Diot, M. Groth, et al. 1998. Respirable mass: vague and indefinable in disease. J. Aerosol Med. 11:5105-5111.
3. Sangwan, S., R. Condos, and G.C. Smaldone. 2003. Lung deposition and respirable mass during wet nebulization. J. Aerosol Med. 16:379-386.
4. Clark, A., and L. Borgström. 2002. In vitro testing of pharmaceutical aerosols and predicted lung deposition from in vitro measurements. In Drug Delivery to the Lung. H. Bisgaard, C. O'Callaghan, and G.C. Smaldone, eds. Marcel Dekker, New York, 105-142.
5. Diot, P., L.B. Palmer, A. Smaldone, et al. 1997. RhDNase I aerosol deposition and related factors in cystic fibrosis. Am. J. Respir. Crit. Care Med. 156:1662-1668.
6. Smaldone, G.C., R.J. Perry, and D.G. Deutsch. 1988. Characteristics of nebulizers used in the treatment of AIDS-related Pneumocystis carinii pneumonia. J. Aerosol Med. 1:113-126.
7. Heyder, J., J. Gebhart, W. Stahlhofen, et al. 1982. Biological variability of particle deposition in the human respiratory tract during controlled and spontaneous mouth-breathing. Ann. Occup. Hyg. 26:137-147.
8. Bennett, W.D., and G.C. Smaldone. 1987. Human variation in peripheral air-space deposition of inhaled particles. J. Appl. Physiol. 62:1603-1610.
9. Smaldone, G.C. 1997. Respiratory physiology in asthma: pulmonary function testing, bronchoprovocation, and mucociliary clearance. In A.P. Kaplan, ed. Allergy, 2nd ed. Churchill Livingstone, New York, 334-344.
10. Smaldone, G.C., W.M. Foster, T.G. O'Riordan, et al. 1993. Regional impairment of mucociliary clearance in chronic obstructive pulmonary disease. Chest 103:1390-1396.
11. Smaldone, G.C., and M.S. Messina. 1985. Flow-limitation, cough, and patterns of aerosol deposition in humans. J. Appl. Physiol. 59:515-520.
12. Smaldone, G.C. 2001. Deposition and clearance: unique problems in the proximal airways and oral cavity in the young and elderly. Respir. Physiol. 128:33-38.
13. Anderson, M., K. Philipson, M. Svartengren, et al. 1995. Human deposition and clearance of 6-μm particle inhaled with an extremely low flow rate. Exp. Lung Res. 21:187-195.
14. Smaldone, G.C., and K. Nikander. 2004. Bench performance and in vivo deposition efficiency of the I-Neb™ adaptive aerosol delivery system (AAD®) during tidal versus slow and deep breathing. Proc. Aerosol Soc. DDL 15:17-20.
15. Amirav, I., and M.T. Newhouse. 2001. Aerosol therapy with valved holding chambers in young children: importance of the facemask seal. Pediatrics 108:389-394.
16. Sangwan, S., B.K. Gurses, and G.C. Smaldone. 2004. Facemasks and facial deposition of aerosols. Pediatr. Pulmonol 37:447-452.
17. Smaldone, G.C. 2004. Respiratory physiology and disease effects on aerosol drug deposition. Respir. Drug Deliv. IX 1:179-186.
18. Trulock, E.P. 1993. Management of lung transplant rejection. Chest 103:1566-1576.
19. Iacono, A.T., B.A. Johnson, W.F. Grgurich, et al. 2006. Randomized trial of inhaled cyclosporine in lung transplant recipients. N. Engl. J. Med. 354:141-150.
20. Iacono, A.T., G.C. Smaldone, R.J. Keenan, et al. 1997. Dose-related reversal of acute lung rejection by aerosolized cyclosporine. Am. J. Respir. Crit. Care Med. 155:1690-1698.
21. Craven, D.E., L.M. Kunches, V. Kilinsky, et al. 1986. Risk factors for pneumonia and fatality in patients receiving continuous mechanical ventilation. Am. Rev. Respir. Dis. 133:792-796.
22. Langer, M., P. Mosconi, M. Cigada, et al. 1989. Long-term respiratory support and risk of pneumonia in critically ill patients. Intensive Care Unit Group of Infection Control. Am. Rev. Respir. Dis. 140:302-330.
23. Fagon, J.Y., J. Chastre, Y. Domart, et al. 1989. Nosocomial pneumonia in patients receiving continuous mechanical ventilation: prospective analysis of 52 episodes with use of a protected specimen brush and quantitative culture techniques. Am. Rev. Respir. Dis. 139:877-884.
24. Kollef, M.H. 1993. Ventilator-associated pneumonia. JAMA 270:1965-1970.
25. Miller, D.D., M.M. Amin, L.B. Palmer, et al. 2003. Aerosol delivery and modern mechanical ventilation: in vitro/in vivo evaluation. Am. J. Respir. Crit. Care Med. 168:1205-1209.
26. Selman, M., T.E. King, and A. Pardo. 2001. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann. Intern. Med. 134:136-151.
27. Kuhn, C., 3rd, J. Boldt, T.E. King, Jr., et al. 1989. An immunohistochemical study of architectural remodeling and connective tissue synthesis in pulmonary fibrosis. Am. Rev. Respir. Dis. 140:1693-1703.
28. Gross, T.J., and G.W. Hunninghake. 2001. Idiopathic pulmonary fibrosis. N. Engl. J. Med. 345:517-525.
29. Park, M.M., A.L. Davis, N.W. Schluger, et al. 1996. Outcome of MDR-TB patients, 1983-1993. Prolonged survival with appropriate therapy. Am. J. Respir. Crit. Care Med. 153:317-324.
30. Raghu, G., K.K. Brown, W.Z. Bradford, et al. 2004. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N. Engl J. Med. 350:125-133.
31. Condos, R., F.P. Hull, N.W. Schluger, et al. 2004. Regional deposition of aerosolized interferon-γ in pulmonary tuberculosis. Chest 125:2146-2155.